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Purpose: To explore the relationship between plasma C-reactive protein (CRP) levels, 
the main ARMS2 gene single nucleotide polymorphism (SNP), and gender in patients 
with neovascular age-related macular degeneration (wet AMD).
Methods: Our study included 131 patients with wetAMD [age-related eye disease study 
(AREDS) category 4] and 153 control participants (AREDS category 1) from two Spanish 
retinal units. CRP levels were determined on blood samples by high-sensitivity ELISA 
assay. According to their CRP level, subjects were categorized into three well-established 
CRP categories: low (<1.00 mg/L, L-CRP), moderate (1–2.99 mg/L, M-CRP), and high 
(>3.00  mg/L, H-CRP). Genomic DNA was extracted from oral swabs using QIAcube 
(Qiagen, Hilden, Germany) and the A69S; rs10490924 of ARMS2 gene was genotyped by 
allelic discrimination with validated TaqMan assays (Applied Biosystems, Foster City, CA, 
USA). Univariate and multivariate logistic regression adjusted for age was used to analyze 
the genomic frequencies and to calculate odds ratio (OR) using SNPStats software.
results: Considering CRP risk categories, H-CRP group showed a significant [OR 4.0 
(1.9–8.3)] association with wetAMD compared to L-CRP group. The risk genotypes 
of A69S (TT) SNPs showed an association with wetAMD risk [OR 14.0 (4.8–40.8)]. 
Interestingly, the gender stratification of the CRP categories showed a significant increase 
in CRP levels in wetAMD women compared with control women [OR 6.9 (2.2–22.3)] and 
with wetAMD men [OR 4.6 (1.3–16.9)]. In addition, the subgroup analysis of CRP within 
A69S genotype and gender showed a link in women between the A69S and CRP levels 
in the AMD group compared to controls [OR 4.2 (1.4–12.6)].
conclusion: Our study shows, for the first time, that a different genetic association 
related with gender could contribute to AMD risk. As a consequence, the risk of female 
gender in the different CRP levels and A69S SNP frequencies could be taken into con-
sideration to the established risk relationship of high levels of CRP and its association 
with risk A69S genotype.
Keywords: c-reactive protein, wet macular degeneration, polymorphism, single nucleotide, gender differences, 
case–control studies
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inTrODUcTiOn
Age-related macular degeneration (AMD) is the leading cause 
of irreversible vision loss among people more than 55  years 
of age in developed countries and can be divided into early 
and late stages. Late AMD is characterized by geographic 
atrophy or choroidal neovascularization (CNV) (wet AMD) 
both of which may lead to central visual impairment or 
irreversible blindness (1, 2). Inflammation and components 
of innate immunity, like complement activation, play a major 
role in the pathophysiology of AMD (3–5). Normal, adaptive 
parainflammation (defined as low-grade chronic inflamma-
tion) exists in the aging retina under physiologic conditions, 
but unbalanced and uncontrolled parainflammation leads to 
a detrimental chronic inflammatory response and contributes 
to the development of early and advanced AMD forms. This 
chronic process is mediated by many genetic and environmen-
tal factors (6).
Inflammatory factors, such as C-reactive protein (CRP), 
interleukin (IL)-6, and amyloid beta levels are increasingly being 
associated with AMD in the scientific literature (7–13). Among 
them, elevated CRP serum levels have been widely associated 
with both AMD development (9, 12, 14, 15) and progression (16). 
Similarly, several single nucleotide polymorphisms (SNP) in the 
complement pathway, particularly in the complement factor H 
(CFH), as well as in the ARMS2 gene region, have been strongly 
associated with prevalence and incidence of AMD (17–19). More 
specifically, the A69S polymorphism has been related to the wet 
form of AMD rather than the atrophic form of the disease (20). 
Systemic CRP, along with genetic variants in the inflammatory 
pathway (CFH) and other pathway (ARMS2) have been associated 
with advanced AMD in age-related eye disease study (AREDS) 
sub-population (15). Although the relationship between CFH 
and CRP has been thoroughly studied by several authors, there 
is a paucity of high quality data directed to study the association 
between ARMS2 and CRP levels.
Moreover, recent studies have shown controversial data about 
the influence of gender in the development and onset of early and 
late AMD. Whereas some studies have not found any relationship 
(1), a recent meta-analysis revealed that some individual studies 
suggested higher rates of neovascular AMD in women, mainly 
based on potentially higher rates of cerebrovascular events (2, 
21). Interestingly, cerebrovascular and cardiovascular incidents 
have been related to increased systemic CRP levels (22).
To elucidate potential relationships between these factors, 
we aimed to investigate the influence of systemic CRP, A69S 
genotype, and gender in a large cohort of wetAMD patients and 
age-matched controls that attended in the Retinal units of two 
tertiary referral centers.
MaTerials anD MeThODs
study Population
Our study included 131 patients with wetAMD (AREDS category 
4) and 153 control participants (AREDS category 1) from 2 tertiary 
referral hospitals: Clinica Universidad de Navarra and Hospital 
Clinic de Barcelona (from the Spanish Multicenter Group on 
AMD and the “Red Temática de Investigación Cooperativa en 
Salud,” RD07/0062, OFTARED RD12/0034 and RD16/0008). All 
participants were of Caucasian origin, completed a demographic 
questionnaire and gave permission for their inclusion in a data-
base (data protection consent). All procedures were performed 
in accordance with the ethical standards of the Institutional 
Ethics Review Board of the Clínica Universidad de Navarra and 
with the 1964 Helsinki Declaration and its later amendments, or 
comparable ethical standards. All subjects gave written informed 
consent. Inclusion criteria for patients with wetAMD included 
the following: diagnosis of AMD with active subfoveal or juxta-
foveolar CNV confirmed by fluorescein angiography (FA) and/or 
optical coherence tomography (OCT) (AREDS category 4). For 
control participants, inclusion criteria were the following: absence 
of drusen or no more than 5 small drusen (≤65 μm), absence of 
retinal pigment abnormalities in the macular area, and absence of 
chorioretinal macular atrophy or any other form of CNV (AREDS 
category 1). Exclusion criteria for this study (for both patients 
with wetAMD and control participants) included: age younger 
than 55 years, the presence of other CNV-related retinal diseases 
(i.e., angioid streaks, nevus in the macular area, toxoplasmosis 
scars, photocoagulation scars in the posterior pole, or polypoidal 
choroidal vasculopathy), history of retinal surgery, retinal disease 
in the studied eye (i.e., diabetic retinopathy or hereditary retinal 
dystrophies), and more than 6 diopters of myopia. DNA analysis 
was performed in 131 controls and 115 wetAMD subjects, the 
remaining samples were not analyzed because of technical 
problems with DNA (e.g., poor quality of DNA, DNA degrada-
tion, and sample collection issues). All cases underwent detailed 
ophthalmologic examination, including visual acuity assessment, 
dilated slit-lamp biomicroscopy, automatic objective refraction, 
color fundus photography, FA, and/or OCT. Controls underwent 
visual acuity assessment, mydriatic fundus examination, and 
measurement of refractive error and axial length.
crP analysis
Samples were obtained from peripheral blood in EDTA containing 
tubes and processed accordingly (1,500 g, 15 min). Plasma high 
sensitive hsCRP levels were determined using a high-sensitivity 
ELISA assay (ICN Pharmaceuticals, Costa Mesa, CA, USA) as 
previously reported (23, 24) and following manufacturer instruc-
tions. All assays were performed in duplicates by investigators 
blinded to the clinical or genetic characteristics of the study sub-
jects. Intra- and inter-assay coefficients of variations were <10%.
As previously reported by other authors (24) the distribution of 
CRP values was not normal (skewness = 1.130, kurtosis = 0.73), 
but the values transformed to the natural logarithm approximated 
a normal distribution (skewness  =  −0.846, kurtosis  =  1.38). 
Logarithmic transformations were used for CRP for analyses with 
continuous variables in order to decrease the effect of extreme 
observations (25).
genotyping
The DNA samples from 131 controls and 115 wetAMD subjects 
were used in this study. Genomic DNA was extracted from oral 
swabs using QIAcube (Qiagen, Hilden, Germany). The control 
and wetAMD cohorts were genotyped for the rs10490924 of 
Table 2 | C-reactive protein (CRP) levels, number of subjects per CRP 
stratification, and A69S genotype for control and wetAMD groups.
control WetaMD P value Or (95%ci)
Mean 
LogCRP ± SEM
1.26 ± 0.04 1.43 ± 0.03 0.001
CRP—n (%) 0.001
L-CRP (<1 mg/L) 41 (26.8) 13 (9.9) 1.00
M-CRP 
(1.0–3.0 mg/L)
64 (41.8) 57 (43.5) 0.007 2.8 (1.3–5.8)
H-CRP 
(3.0–10.0 mg/L)
48 (31.4) 61 (46.6) 0.0001 4.0 (1.9–8.3)
ARMS2 A69S—n (%) n = 131 n = 115 <0.0001
GG 85 (64.9) 36 (31.3) 1.00
GT 41 (31.3) 54 (47.0) 9.0 × 10−5 3.7 (2.0–6.8)
TT 5 (3.8) 25 (21.7) 1.0 × 10−7 14.0 (4.8–40.8)
MAF T: 0.19 T: 0.45 7.6 × 10−10 3.4 (2.3–5.1)
Mean LogCRP between controls and wetAMD participants was statistically 
significant (p < 0.001) based on lineal regression test and data on single nucleotide 
polymorphisms and CRP levels were analyzed by univariate logistic regression adjusted 
by age and gender. *L-CRP (low C-reactive protein, <1 mg/L), M-CRP (moderate 
C-reactive protein, 1.0–3.0 mg/L), and H-CRP (high C-reactive protein, 3.0–10.0 mg/L). 
SEM; OR, odds ratio; CI, confidence interval; MAF, minor allele frequency. Letters T and 
G: nucleotides for the ARMS2 A69S. ORs >1 imply that was associated with increased 
risk of wetAMD when compared with the control (reference) group. Significant p-values 
were highlighted in bold.
Table 1 | Demographics for the total population and the subgroup which 
underwent A69S genotyping analysis.
control WetaMD P value 
(control vs. 
wetaMD)
Total population
Men n (%) 71 (46.4) 53 (40.5)
Age (years) 73.30 ± 0.86 76.83 ± 0.93 0.007
Women n (%) 82 (53.6) 78 (59.5) 0.314
Age (years) 73.87 ± 0.77 76.38 ± 0.80 0.025
Total n 153 131
Age (years) 73.60 ± 0.57 76.56 ± 0.61 0.0005
subgroup Dna analysis
Men n (%) 63 (48.1) 48 (41.7)
Age (years) 72.79 ± 0.89 77.10 ± 0.93 0.001
Women n (%) 68 (51.9) 67 (58.3) 0.369
Age (years) 73.87 ± 0.89 76.36 ± 0.91 0.052
Total n 131 115
Age (years) 73.35 ± 0.63 76.67 ± 0.66 0.0003
Age is shown in years (mean ± SEM). No significant differences were observed in 
gender distribution for the total population (p = 0.314) and the genotyped participants 
(p = 0.369). Comparisons in age within the total population between control men 
and women (p = 0.622), wetAMD men and women (p = 0.721) were not statistically 
significant. Comparisons within the genotyped population between control men and 
women (p = 0.395), wetAMD men and women (p = 0.577) were not statistically 
significant. Age analysis was performed by student’s t-test and chi-square was used 
for gender distribution. Significant p-values were highlighted in bold.
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ARMS2 gene by allelic discrimination with a validated assay 
(TaqMan; Applied Biosystems, Foster City, CA, USA) using 
real-time PCR (PE7300; Applied Biosystems), according to the 
manufacturer’s instructions.
statistical analysis
Age analysis was performed by student’s t-test and chi-square test 
was used for gender distribution analysis. Levels of hsCRP and 
LogCRP were analyzed by lineal regression adjusted by age. The 
frequencies of alleles, genotypes, and haplotypes were calculated 
in all groups and were compared using a chi-square test and 
Fisher’s exact test, and corresponding ORs were calculated. A69S 
was in Hardy–Weinberg equilibrium.
Univariate logistic regression, adjusted by age and gender, 
and only by age for gender-based analysis, was used to estimate 
the ORs and 95% confidence intervals (95% CI) using SNPStats 
software (26). Analyses for each genetic variant were performed 
independently of other variants using codominant, dominant, 
recessive, and/or overdominant genetic models in base Akaike 
information, which chooses the inheritance model that best fits 
the data. A p value <0.05 was considered statistically significant.
resUlTs
crP analysis
Demographics for gender distribution and mean age in control 
and wetAMD groups for the total population and the individuals 
that underwent A69S genotyping analysis are shown in Table 1. 
The mean age (years ± SEM) was 73.60 ± 0.57 for controls and 
76.56 ±  0.61 for wetAMD group (p =  0.0005). The percentage 
of women was balanced in both controls and wetAMD patients 
(53.6 vs. 59.5%, respectively). No differences in age were observed 
between men and women both in control (73.30 ±  0.86 and 
73.87  ±  0.77, respectively; p  =  0.622) and wetAMD groups 
(76.83 ± 0.93 and 76.38 ± 0.80, respectively; p = 0.721). In men, 
the mean age was 73.30 ± 0.86 in controls and 76.83 ± 0.93 in 
wetAMD group (p = 0.007) and 73.87 ± 0.77 in control women vs. 
76.38 ± 0.80 in wetAMD women (p = 0.025). Mean LogCRP lev-
els, CRP distribution, and A69S genotypes according to wetAMD 
cases and controls are shown in Table 2. Regarding CRP systemic 
levels, significantly greater mean hsCRP (mg/L) levels normalized 
by Log function (24) were observed in wetAMD vs. controls (1.43 
vs. 1.26, p < 0.001). Without normalization, these greater mean 
hsCRP levels were still statistically significant (3.47 vs. 2.71 mg/L, 
p < 0.001) and wetAMD individuals showed a 28% greater hsCRP 
level compared to controls. Usually, CRP levels are stratified into 
low (L-CRP, <1.0 mg/L), moderate (M-CRP, 1.0–3.0 mg/L), and 
high (H-CRP, 3.0–10.0  mg/L) (23, 24). In our study, we found 
that there was a statistical difference (p = 0.001) in CRP distribu-
tion between control and wetAMD participants. H-CRP levels 
were observed in 46.6% of wetAMD individuals compared to a 
31.4% in controls, whereas L-CRP levels were observed in 9.9% 
of wetAMD group compared to 26.8% of controls. Compared to 
the L-CRP group, a greater wetAMD risk was observed for the 
M-CRP group (OR 2.8 95% CI, 1.3–5.8, p = 0.007) and H-CRP 
group (OR 4.0 95% CI, 1.9–8.3, p = 0.0001).
ARMS2 a69s genotyping
The distribution of genotypes for the A69S polymorphism was 
in Hardy–Weinberg equilibrium in the study population. The 
distribution of ARMS2 A69S genotypes was different between 
controls and wetAMD cases (p <  0.0001, Table 2), as we have 
described previously (20). The study of allelic frequencies showed 
Table 3 | Subgroup analysis by gender.
Men Women
controls WetaMD P value Or (95% ci) controls wetaMD P value Or (95% ci)
Number per group—n 71 53 82 78
Mean hsCRP (mg/L) ± SEM 2.63 ± 0.31 3.13 ± 0.32 0.275 2.79 ± 0.24 3.71 ± 0.25 0.009
Mean LogCRP ± SEM 1.21 ± 0.06 1.36 ± 0.05 0.140 1.30 ± 0.04 1.49 ± 0.03 0.002
C-reactive protein (CRP)—n (%)
L-CRP 20 (28.2) 9 (17.0) 1.00 21 (25.6) 4 (5.1) 1.00
M-CRP 34 (47.9) 24 (45.3) 0.5 1.6 (0.6–5.0) 30 (36.6) 33 (42.3) 0.002 5.7 (1.8–18.7)
H-CRP 17 (23.9) 20 (37.7) 0.08 2.6 (0.9–7.2) 31 (37.8) 41 (52.6) 0.0004 6.9 (2.2–22.3)
ARMS2 A69S—n (%) n = 63 n = 48 n = 68 n = 67
GG 40 (63.5) 21 (43.8) 1.00 45 (66.2) 15 (22.4) 1.00
GT 21 (33.3) 17 (35.4) 0.39 1.5 (0.6–3.51) 20 (29.4) 37 (55.2) 1.2 × 10−5 8.8 (3.7–21.4)
TT 2 (3.2) 10 (20.8) 0.003 9.7 (1.9–50.1) 3 (4.4) 15 (22.4) 8.3 × 10−6 22.8 (5.4–95.2)
MAF T; 0.20 T; 0.39 0.002 2.5 (1.4–4.6) T; 0.19 T; 0.50 1.1 × 10−7 4.2 (2.4–7.3)
Mean C-reactive protein (CRP) level and number of men and women divided into control and wetAMD groups according to CRP groups and genotype frequencies.
L-CRP (low C-reactive protein, <1 mg/L), M-CRP (moderate C-reactive protein, 1.0–3.0 mg/L), and H-CRP (high C-reactive protein, 3.0–10.0 mg/L). LogCRP levels were analyzed 
by lineal regression and adjusted by age. CRP groups and A69S genotyping were analyzed by univariate logistic regression adjusted by age. SEM; OR, odds ratio; CI, confidence 
interval; MAF, minor allele frequency. Letters T and G: nucleotides for the ARMS2 A69S. ORs >1 imply that was associated with increased risk of wetAMD when compared with the 
control (reference) group. Significant p-values were highlighted in bold. 
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significant differences between wetAMD and control groups (OR 
3.4 CI: 2.3–5.1; p = 7.6 × 10−10, Table 2). The percentage of risk 
genotypes (A69S GT and TT) was greater in the wetAMD group 
compared to the control group (68.7 vs. 35.1%). GT genotype 
showed a strong association with risk of wetAMD (OR 3.7 CI: 
2.0–6.8; p = 9.0 × 10−5) which was even greater for the TT-risk 
genotype, with a 14-fold increase in wetAMD group vs. controls 
(OR 14.0 CI: 4.8–40.8; p = 1.0 × 10−7, Table 2).
crP and ARMS2 a69s genotypes and 
gender influence
CRP Analysis by Gender
Descriptive statistics divided by gender, control and wetAMD 
groups, CRP levels, genotype frequencies, and demographic 
factors are disclosed in Tables 3–6. Significantly higher LogCRP 
and hsCRP levels were observed in women between control and 
wetAMD groups (p = 0.002 and p = 0.009, respectively, Table 3), 
while men did not show differences between these groups 
(p = 0.140 and p = 0.275, respectively, Table 3). Women showed 
greater wetAMD risk in M-CRP [OR 5.7 (1.8–18.7); p = 0.002] 
and H-CRP groups [OR 6.9 (2.2–22.3); p =  0.0004] compared 
to the L-CRP group (Table 3). The percentage of patients with 
H-CRP levels was greater in wetAMD vs. controls in women 
[52.6 vs. 37.8%, OR = 6.9 (2.2–22.3), p = 0.0004], but no differ-
ences were observed in men [37.7 vs. 23.9%, OR = 2.6 (0.9–7.2), 
p = 0.08] (Table 3).
ARMS2 A69S Genotypes Analysis by Gender
Subgroup analysis by A69S genotypes and gender revealed a risk 
association for TT genotype and wetAMD in men [OR 9.7 (1.9–
50.1); p = 0.003, Table 3]. However, this association was observed 
in women for both the GT [OR 8.8 (3.7–21.4); p = 1.2 × 10−5] and 
TT [OR 22.8 (5.4–95.2); p = 8.3 × 10−6, Table 3] genotypes when 
comparing control and wetAMD groups. The allelic frequency 
studies also corroborated the genotyping results, and differences 
between the control group vs. wetAMD were observed in men 
[OR 2.5 (1.4–4.6), p = 0.002] and women, who showed a greater 
association [OR 4.2 (2.4–7.3), p = 1.1 × 10−7; Table 3].
The results obtained from the division of control and wetAMD 
individuals into men and women are shown in Table  4. The 
analysis of the LogCRP levels showed that wetAMD women had 
significantly higher CRP levels compared with wetAMD men 
(1.49 vs. 1.36, p = 0.036, Table 4). Further, no differences were 
reported in the control group with regards to CRP stratification 
levels between women and men (Table 4; Figure 1). However, 
women with H-CRP levels showed higher risk of wetAMD 
compared to men [52.6 vs. 37.7%, OR 4.6 (1.3–16.9); p = 0.02]. 
No differences were observed for M-CRP or L-CRP groups, 
and interestingly, L-CRP levels were observed only in 5.1% of 
wetAMD women compared to 17% of wetAMD men (Table 4; 
Figure 1).
With regards to A69S genotypes and gender of the same group, 
differences between wetAMD men and women were only observed 
in GT genotype frequencies [OR 3.1 (1.3–7.6); p = 0.016, Table 4; 
Figure 2]. The allelic study did not show significant differences 
for the T risk allele between wetAMD women and men, although 
the allelic frequency in women was higher than in men [T; 0.39 
vs. 0.50, p = 0.10; OR 1.6 (0.98–2.7), Table 4; Figure 2].
ARMS2 A69S Genotypes and CRP Combined 
Analysis by Gender
The distribution of A69S genotypes and stratified CRP levels 
divided by gender in both control and wetAMD patients is shown 
in Tables 5 and 6, respectively. These tables also show p-values of 
the interaction between CRP levels and A69S, based on a model 
controlling for dominant genotypes (GT/TT vs. GG) and CRP 
(L-CRP and M/H-CRP) adjusted by age. Normal population usu-
ally shows L-CRP levels and taking into account that a CRP level 
Table 5 | Dominant model of the frequencies observed for the ARMS2 A69S genotype within CRP groups dividing total population, men and women into control and 
wetAMD groups.
arMs2-a69s Total population Men Women
control WetaMD P value Or (95% ci) control WetaMD P value Or (95% ci) control WetaMD P value Or (95% ci)
l-crP
GG 22 5 1.00 8 4 1.00 14 1 1.00
GT/TT 12 7 0.19 2.6 (0.7–9.9) 9 5 0.95 1.1 (0.2–5.6) 3 2 0.14 9.3 (0.6–139.6)
MAF T; 0.18 T; 0.42 0.03 3.2 (1.1–8.9) T; 0.25 T; 0.39 0.35 1.9 (0.6–6.4) T; 0.09 T; 0.50 0.03 10.3 (1.4–75.7)
M/h-crP
GG 63 31 1.00 32 17 1.00 31 14 1.00
GT/TT 34 72 6.5 × 10−7 4.3 (2.4–7.8) 14 22 0.014 3.0 (1.2–7.2) 20 50 2.4 × 10−5 5.5 (2.4–12.5)
MAF T; 0.20 T; 0.46 5.3 × 10−8 3.3 (2.1–5.2) T; 0.17 T; 0.38 0.001 3.0 (1.5–6.0) T; 0.22 T; 0.50 2.0 × 10−5 3.4 (1.9–6.1)
L-CRP (low C-reactive protein, <1 mg/L) and M/H-CRP (moderate-high C-reactive protein, 1.0–10.0 mg/L). Data were analyzed by univariate logistic regression adjusted by age and 
gender for the total population and by age for men and women subgroups. OR, odds ratio; CI, confidence interval; MAF, minor allele frequency. Letters T and G: nucleotides for the 
ARMS2 A69S. ORs >1 imply that was associated with increased risk of wetAMD when compared with the control (reference) group. Significant p-values were highlighted in bold.
Table 4 | Subgroup analysis for control and wetAMD individuals divided into gender, according to CRP groups and genotype frequencies.
control WetaMD
Men Women P value Or (95% ci) Men Women P value Or (95% ci)
Number per group—n 71 82 53 78
Mean hsCRP (mg/L) ± SEM 2.63 ± 0.31 2.79 ± 0.24 0.696 3.13 ± 0.32 3.71 ± 0.25 0.154
Mean LogCRP ± SEM 1.21 ± 0.06 1.30 ± 0.04 0.427 1.36 ± 0.05 1.49 ± 0.03 0.036
C-reactive protein (CRP)—n (%)
L-CRP 20 (28.2) 21 (25.6) 1.00 9 (17.0) 4 (5.1) 1.00
M-CRP 34 (47.9) 30 (36.6) 0.86 1.2 (0.5–2.6) 24 (45.3) 33 (42.3) 0.12 3.1 (0.8–11.2)
H-CRP 17 (23.9) 31 (37.8) 0.28 1.7 (0.7–4.0) 20 (37.7) 41 (52.6) 0.02 4.6 (1.3–16.9)
ARMS2 A69S—n (%) n = 63 n = 68 n = 48 n = 67
GG 40 (63.5) 45 (66.2) 1.00 21 (43.8) 15 (22.4) 1.00
GT 21 (33.3) 20 (29.4) 0.70 0.9 (0.4–1.8) 17 (35.4) 37 (55.2) 0.016 3.1 (1.3–7.6)
TT 2 (3.2) 3 (4.4) 1.00 1.3 (0.2–8.3) 10 (20.8) 15 (22.4) 0.19 2.2 (0.8–6.2)
MAF T; 0.20 T; 0.19 1.00 0.9 (0.5–1.7) T; 0.39 T; 0.50 0.10 1.6 (0.9–2.7)
L-CRP (low C-reactive protein, <1 mg/L), M-CRP (moderate C-reactive protein, 1.0–3.0 mg/L), and H-CRP (high C-reactive protein, 3.0–10.0 mg/L). LogCRP levels were analyzed 
by lineal regression and adjusted by age. CRP groups and A69S genotyping were analyzed by univariate logistic regression adjusted by age. SEM; OR, odds ratio; CI, confidence 
interval; MAF, minor allele frequency. Letters T and G: nucleotides for the ARMS2 A69S. ORs >1 imply that was associated with increased risk of wetAMD when compared with the 
control (reference) group. Significant p-values were highlighted in bold.
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higher than 1  mg/L is considered a cardiovascular risk factor. 
Therefore, we combined both categories (M-CRP and H-CRP) 
into a single one (M/H-CRP) to assess the influence of CRP levels 
on the risk of wetAMD, depending on genotypes. A very strong 
relationship was observed between A69S risk genotypes, CRP 
levels, and female gender. In the total study cohort, the allele fre-
quency study showed a significant association of the T risk allele 
in both CRP levels analyzed [L-CRP; OR = 3.2 (1.1–8.9), p = 0.03, 
and M/H-CRP; OR = 3.3 (2.1–5.2), p = 5.3 × 10−8, Table 5]. In 
M/H-CRP level, women showed a greater association of T risk 
allele compared with men [OR 3.4 (1.9–6.1), p = 2.0 × 10−5 and OR 
3.0 (1.5–6.0), p = 0.001, Table 5; Figure 3]. Considering the GT/
TT risk genotypes this difference is even greater. The total popula-
tion showed a 4.3-fold increase likelihood of wetAMD in GT/
TT genotypes compared to GG [OR 4.3 (2.4–7.8), p = 6.5 × 10−7, 
Table  5], however, was women carrying GT/TT distribution 
where the risk of wetAMD vs. control was the greatest [women; 
OR 5.5 (2.4–12.5), p =  2.4 ×  10−5 and men; OR 3.0 (1.2–7.2), 
p = 0.014, Table 5]. We further explored these differences and 
found that, women with M/H-CRP and GT/TT genotypes have a 
threefold greater risk of wetAMD than men with such conditions 
[OR 2.8 (1.2–6.6), p = 0.03, Table 6; Figure 3]. Finally, a trend 
for a protective association was in the control group for women 
carrying GG and L-CRP compared to men [OR 0.2 (0.04–1.0), 
p = 0.07, Table 6].
DiscUssiOn
The present study describes, for the first time, a novel association 
between gender, CRP (a systemic marker of inflammation), the 
A69S SNP in the ARMS2 gene, and wet AMD. We found that 
CRP is a multiplying wet AMD risk factor to the ARMS2 SNP 
in women, and we observed a threefold higher wetAMD risk for 
women carrying the GT or TT at-risk allele and with intermediate 
or high CRP levels compared to men.
Age-related macular degeneration is a chronic and complex 
disease affecting people older than 55 years (1) in which several 
genetic and environmental factors have an influence on its 
FigUre 2 | Percentage of individuals according to A69S genotypes divided 
by gender (men: upper row and women: lower row) and study groups 
(controls: left column and wetAMD: right column). L-CRP (low C-reactive 
protein, <1 mg/L; light gray), M-CRP (moderate C-reactive protein, 
1.0–3.0 mg/L; medium gray), and H-CRP (high C-reactive protein, 3.0–
10.0 mg/L; dark gray). Letters T and G: nucleotides for the ARMS2 A69S.
FigUre 1 | Percentage of individuals according to C-reactive protein (CRP) 
level stratification divided by gender (men: upper row; women: lower row) 
and study groups (controls: left column and wet age-related macular 
degeneration: right column). L-CRP (low C-reactive protein, <1 mg/L; light 
gray), M-CRP (moderate C-reactive protein, 1.0–3.0 mg/L; medium gray), 
and H-CRP (high C-reactive protein, 3.0–10.0 mg/L; dark gray). Letters T 
and G: nucleotides for the ARMS2 A69S.
Table 6 | Dominant model of the frequencies observed for the ARMS2 A69S genotype within CRP groups between control and wetAMD in men and women 
separately.
arMs2-a69s control WetaMD
Men Women P value Or (95% ci) Men Women P value Or (95% ci)
l-crP
GG 8 14 1.00 4 1 1.00
GT/TT 9 3 0.07 0.2 (0.04–1.0) 5 2 1.0 1.6 (0.1–24.6)
MAF T; 0.25 T; 0.09 0.10 0.3 (0.06–1.1) T; 0.39 T; 0.50 0.9 1.5 (0.2–10.3)
M/h-crP
GG 32 31 1.00 17 14 1.00
GT/TT 14 20 0.4 0.7 (0.3–1.6) 22 50 0.03 2.8 (1.2–6.6)
MAF T; 0.17 T; 0.22 0.5 0.7 (0.3–1.5) T; 0.38 T; 0.50 0.11 1.6 (0.9–2.8)
L-CRP (low C-reactive protein, <1 mg/L) and M/H-CRP (moderate-high C-reactive protein, 1.0–10.0 mg/L). Data were analyzed by univariate logistic regression adjusted by age. 
OR, odds ratio; CI, confidence interval; MAF, minor allele frequency. Letters T and G: nucleotides for the ARMS2 A69S. ORs >1 imply that was associated with increased risk of 
wetAMD when compared with the control (reference) group. Significant p-values were highlighted in bold.
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progression (27, 28). Although serum CRP levels have gained 
greater importance as a risk marker in cardiovascular disease 
(CVD), the magnitude of its risk potential has been debated 
(29). Consistent evidence of a significant association between 
elevated serum CRP and late AMD supports the hypothesis that 
higher levels of CRP (>3  mg/L) are associated with a twofold 
higher likelihood of late AMD. In contrast, the evidence of an 
association between CRP and early AMD is weaker (23, 30). This 
difference has been previously investigated for other diseases 
in which CRP is considered an inflammatory marker, such as 
CVD (31), obstructive sleep apnea (32), and obesity (33), with 
controversial results. In the present study, we confirmed our 
previous results where a relationship between A69S and the risk 
of wetAMD was observed (20). We have found a fourfold increase 
of wetAMD likelihood in GT and a 14-fold increase for the at-risk 
TT genotype. Since elevated CRP confers a higher risk of AMD 
(30), the combination of these findings suggests that the risk allele 
might contribute to the development of AMD. In our study, we 
observed that ARMS2 A69S heterozygous and homozygous risk 
alleles along with moderate CRP levels seem to be associated with 
wet AMD in men and women.
ARMS2 protein is a component of the extracellular matrix of 
the choroid that some authors locate in the mitochondria (34). 
Recent studies in rats, using electron microscopy, have demon-
strated disorganization and swelling of mitochondria’s after CRP 
injection in cardiomyocytes from ischemic carotids (35). Other 
authors have found that ARMS2 is located in the cytosol colocal-
ized with cellular skeleton (microtubules and actin filaments), 
FigUre 3 | Percentage of individuals according to men (a) and women (b) and to C-reactive protein (CRP) stratified groups (L-CRP: upper row and M/H-CRP: 
lower row) and A69S genotype (light gray: GG and dark gray: GT/TT). L-CRP (low C-reactive protein, <1 mg/L) and M/H-CRP (moderate-high C-reactive protein, 
1.0–10.0 mg/L). Letters T and G: nucleotides for the ARMS2 A69S.
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suggesting that A69S may gain function to interact with the 
cytoskeleton (36). Furthermore, CRP is involved in microtubules 
stabilization by inhibiting neutrophil movement through the 
kinases pathway (37). Finally, some authors have found signifi-
cantly higher CRP deposits in the Bruch’s membrane and retinal 
and choroid vessels of wet AMD eyes compared to aged controls 
and AMD human donors (38).
Currently, there is great concern about the role of gender as 
potential bias that may influence results of clinical trials and affect 
diagnostic or treatment decisions. As a consequence, gender per-
spective has recently become a major factor to be considered in 
clinical research and especially in genetics (39), since some differ-
ences related to gender may commonly be missed and/or remain 
unrevealed. To ascertain these potential differences, we considered 
the parameters separately for each gender. After dividing the study 
cohort into men and women, we observed a strong association 
between high levels of CRP and wetAMD in women, which was 
not seen in men. Moreover, in the subanalysis performed by 
gender in control and wetAMD groups, higher levels of CRP were 
more frequently observed in women compared with men within 
the wetAMD group. These results could suggest an association of 
female gender and high CRP levels and allegedly, inflammation, 
in the development of wet AMD. These findings highlight the 
potential usefulness of systemic CRP as a marker of wet AMD in 
women, as a novel risk factor that may also be considered along 
with the well-established factors for AMD. Interestingly, wetAMD 
men only showed a 56.2% of heterozygous and at-risk homozygous 
genotypes compared to the 77.6% observed in wetAMD women. 
Furthermore, women with GT genotype had a threefold increase 
risk of wetAMD compared to men.
Understanding the combined effects and interactions among 
specific genotypes and risk factors in wet AMD may provide new 
insights into the complex etiology of such chronic condition. In fact, 
the study of the association between AMD genetics, inflammatory 
factors, and gender is a rapidly evolving research field. A recent 
study, for example, described that DAPL1 is an AMD-associated 
gene and that this disease association is female-specific (40).
Despite the growing consensus that chronic inflammation is 
an important factor in the pathogenesis of AMD, few studies have 
studied the association of ARMS2 and systemic inflammatory 
markers such as CRP. Hence, we also analyzed the correlation 
between serum CRP categories and ARMS2 A69S genotypes in 
the total population and stratified by gender. In our study, in 
agreement with the results observed by Seddon et  al. (15), we 
observe that the ARMS2 at-risk allele for AMD is strongly associ-
ated with moderate and high CRP systemic levels with a fourfold 
increased risk, suggesting that probably this association is related 
to low-grade chronic systemic inflammation (22).
The most novel finding in our study is related to gender. We 
found that women with intermediate-high CRP and carrying the 
A69S at-risk alleles had almost a sixfold greater risk of wetAMD 
compared to the threefold risk observed in men. This was 
confirmed when genders were compared within groups, and an 
almost threefold higher risk of wetAMD was observed in women 
with the at-risk GT/TT alleles and moderate-high CRP levels 
compared to men.
We hypothesized that a plausible biological explanation to 
these gender-related differences reported could rely on the differ-
ent hormone levels observed in men and women. Oral hormone 
therapy and CRP levels in postmenopausal women have shown 
a direct relationship (41). Further, a biological pathway for AMD 
that features hormone replacement therapy includes estrogen 
receptors 1 and 2. Both proteins have been observed in the human 
retina, suggesting that estrogens play a role in the pathogenesis 
of AMD (42, 43). Estrogen controls the expression of chitinase 
3-like-1 protein (YKL-40), a molecule found in choroidal neo-
vascular membranes. Lower levels of estrogen may trigger the 
upregulation of YKL-40 and play a role in the development of 
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neovascular AMD (44). Moreover, estrogens have an antioxidant 
effect by inhibiting lipid peroxidation, which provides protection 
against oxidative damage in the retina caused by the aging pro-
cess (45). Women are mostly exposed to hormonal changes with 
aging and especially after their mid-life, which may contribute 
to a greater risk compared to men who usually show more stable 
hormonal levels. However, the exact mechanisms underlying 
these differences are still unclear and these preliminary results 
come from preclinical investigations using cell culture and ani-
mal models.
This is the first study directed to evaluate the relationship 
between the ARMS2 A69S distribution, serum CRP levels, and 
gender in AMD patients and controls. Interestingly, we have 
found a very strong association in women between the ARMS2 
A69S and CRP levels in the AMD group compared to controls. 
The mechanisms and associations related to the ARMS2 locus 
and CRP remain to be elucidated. In our study, it seems that the 
ARMS2 and intermediate-high CRP levels provide greater risk of 
wetAMD, especially in women.
However, it should be noted that these findings may be consid-
ered within the context of a selected population and some limita-
tions should be acknowledged such as sample size. Therefore, 
more studies to replicate this association in an independent 
sample set in a stronger powered analysis are needed. Moreover, 
as other authors have also reported for CVD, CRP levels can be 
confounded by obesity, ethnicity, gender, and other comorbidities 
(31). Future studies must consider the inclusion of factors, such 
as smoking, body mass index, serum cholesterol, hypertension, 
and the use of hormone replacement therapy in the variance 
component model.
In spite of the limitations described above, our study shows 
several strengths including that this is the first time that a gender-
based analysis on A69S genotype frequencies is performed. Despite 
the relatively low number of samples in the gender subgroups, the 
magnitude of the associations and the significance values obtained 
are strong enough to consider these aspects for future prospective 
and retrospective studies. These data can serve as a starting point 
for prospective trials evaluating such associations. Taking into 
account these results, a potential therapeutic approach could be 
directed to modify this systemic inflammation status, especially 
among those genetically high-risk individuals carrying the at-risk 
alleles in order to reduce the likelihood of wet AMD and, accord-
ing to other studies, also other forms of late AMD (46).
In conclusion, we have observed that women with high CRP 
levels showed higher risk of wetAMD than men, suggesting that 
systemic CRP levels could be useful as an important multiplying 
factor to the already established genetic factors involved in the 
development of wet AMD. These individuals should be prioritized 
for interventional studies directed to prevent the progression of 
the disease (47). One proposal for those at-risk populations has 
been the inhibition of monomeric-CRP for local treatment of 
vascular disease (48) and reduction of myocardial infarct size (49) 
in at-risk areas. In line with this, monomeric-CRP has shown to 
induce an inflammatory phenotype (50) and blood–retinal bar-
rier disruption in RPE cells (51). Given the similarities of risk fac-
tors between CVD and AMD, this approach could be considered 
as a local adjuvant therapy in future new strategies for patients 
at greater risk, such as women with high CRP levels and at-risk 
A69S genotype (52). This could contribute to a better quality of 
life and reduce personal burden for AMD patients.
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